FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1544652079> ?p ?o ?g. }

• W1544652079 endingPage "26" @default.
• W1544652079 startingPage "25" @default.
• W1544652079 abstract "The risks of benzodiazepine use, both short- and long-term, have long been known 1-3. Furthermore, they are undoubtedly drugs associated with problems on attempted reduction in dosage or withdrawal. The discontinuation syndrome can be severe and can prevent the long-term user from ever stopping the medication. Discontinuation is a desirable goal with both anxiolytics and hypnotics 4. It is thus apparent that guidance is needed on efficacious, safe and cost-effective measures to facilitate withdrawal from benzodiazepine use. In this context, the review by Parr et al. is to be welcomed. It is a thorough evaluation of the problem of selecting such regimens. Nevertheless, some caveats can be entered. First, a systematic review, of which this is an excellent example, can be qualitative, describing available trials in terms of their strengths and weaknesses, and their relevance to clinical practice, or quantitative wherein results are combined from various studies 5. However, both may overlook the purpose of an included trial. Not all are primarily efficacy studies but pilot studies or proof-of-concept, and may be underpowered or adopt suboptimal designs. Therefore, some appraisal of the background rationale is helpful. Also, separate appraisal of techniques used to withdraw from anxiolytic as contrasted with hypnotic benzodiazepines is helpful. Adequate follow-up is essential, as relapse is so frequent. As with any therapeutic procedure, the risk/benefit ratio is the crucial variable. Not only is it necessary to establish that a statistically significant difference exists between the trial treatment and the routine treatment or placebo, but the effect size is also crucial. Is the difference of any clinical importance—essentially an informed value judgement? Table 3 is invaluable in setting out both significances and the differences in discontinuation rates. It makes gloomy reading. Simple general practitioner (GP) intervention is not very effective, and more intensive measures help only about half the patients. Of course, these patients are typically those with a poor prognosis, in that previous withdrawal attempts have failed. But what is this comparator ‘routine care’. ‘Routine lack of care’ is sometimes more evident, so that medico-legal considerations are becoming more salient. Many expert GPs are prepared to opine that benzodiazepine treatment extending beyond 2–4 weeks is a breach of duty of care. It may yet be that the law will govern our use of these drugs rather than medical science. The therapeutic landscape has changed in the last few years. The licensing of selective serotonin re-uptake inhibitors (SSRIs) and pregabalin for anxiety disorders and of melatonin agonists for insomnia has opened up the prescribers' therapeutic choices. Accordingly, the use of benzodiazepines can be largely avoided, especially as the newer drugs are generally better tolerated without a risk of dependence or abuse. The authors rightly draw attention to selecting a sequence of treatments and not simply contemporaneous comparisons. A stepped-care approach was suggested by Russell & Lader 6 in which the first two steps involved primary care practitioners—a minimal intervention strategy, then systematic tapering for the failures. Hospital-based schedules then followed but the procedures became more elaborate and consumed more resources. An earlier meta-analysis of available studies suggested that the empirical protocol was supported by the results of controlled clinical trials 7. I would urge the present authors to apply their analytical skills in evaluating the welter of disparate studies to developing this theme of stepped care, so we can give practical evidence-based advice to doctors 8 and patients 9. And not before time! 10. None." @default.
• W1544652079 created "2016-06-24" @default.
• W1544652079 creator A5031620491 @default.
• W1544652079 date "2009-01-01" @default.
• W1544652079 modified "2023-09-26" @default.
• W1544652079 title "[Commentary] COMING OFF TRANQUILLIZERS-A SISYPHEAN TOIL" @default.
• W1544652079 cites W101037913 @default.
• W1544652079 cites W1965539514 @default.
• W1544652079 cites W1975048253 @default.
• W1544652079 cites W2061497773 @default.
• W1544652079 cites W2095280572 @default.
• W1544652079 cites W2097536190 @default.
• W1544652079 doi "https://doi.org/10.1111/j.1360-0443.2008.02402.x" @default.
• W1544652079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19133885" @default.
• W1544652079 hasPublicationYear "2009" @default.
• W1544652079 type Work @default.
• W1544652079 sameAs 1544652079 @default.
• W1544652079 citedByCount "5" @default.
• W1544652079 countsByYear W15446520792013 @default.
• W1544652079 countsByYear W15446520792015 @default.
• W1544652079 countsByYear W15446520792016 @default.
• W1544652079 crossrefType "journal-article" @default.
• W1544652079 hasAuthorship W1544652079A5031620491 @default.
• W1544652079 hasBestOaLocation W15446520791 @default.
• W1544652079 hasConcept C118552586 @default.
• W1544652079 hasConcept C126322002 @default.
• W1544652079 hasConcept C151730666 @default.
• W1544652079 hasConcept C15744967 @default.
• W1544652079 hasConcept C170493617 @default.
• W1544652079 hasConcept C177713679 @default.
• W1544652079 hasConcept C2778173252 @default.
• W1544652079 hasConcept C2778715236 @default.
• W1544652079 hasConcept C2779343474 @default.
• W1544652079 hasConcept C71924100 @default.
• W1544652079 hasConcept C86803240 @default.
• W1544652079 hasConceptScore W1544652079C118552586 @default.
• W1544652079 hasConceptScore W1544652079C126322002 @default.
• W1544652079 hasConceptScore W1544652079C151730666 @default.
• W1544652079 hasConceptScore W1544652079C15744967 @default.
• W1544652079 hasConceptScore W1544652079C170493617 @default.
• W1544652079 hasConceptScore W1544652079C177713679 @default.
• W1544652079 hasConceptScore W1544652079C2778173252 @default.
• W1544652079 hasConceptScore W1544652079C2778715236 @default.
• W1544652079 hasConceptScore W1544652079C2779343474 @default.
• W1544652079 hasConceptScore W1544652079C71924100 @default.
• W1544652079 hasConceptScore W1544652079C86803240 @default.
• W1544652079 hasIssue "1" @default.
• W1544652079 hasLocation W15446520791 @default.
• W1544652079 hasLocation W15446520792 @default.
• W1544652079 hasOpenAccess W1544652079 @default.
• W1544652079 hasPrimaryLocation W15446520791 @default.
• W1544652079 hasRelatedWork W1968748679 @default.
• W1544652079 hasRelatedWork W1987330082 @default.
• W1544652079 hasRelatedWork W2065430497 @default.
• W1544652079 hasRelatedWork W2077182644 @default.
• W1544652079 hasRelatedWork W2139293776 @default.
• W1544652079 hasRelatedWork W2156326304 @default.
• W1544652079 hasRelatedWork W2748952813 @default.
• W1544652079 hasRelatedWork W2766844642 @default.
• W1544652079 hasRelatedWork W2899084033 @default.
• W1544652079 hasRelatedWork W4362559955 @default.
• W1544652079 hasVolume "104" @default.
• W1544652079 isParatext "false" @default.
• W1544652079 isRetracted "false" @default.
• W1544652079 magId "1544652079" @default.
• W1544652079 workType "article" @default.